23 September 2020

Annemiek van Spriel and Laia Querol-Cano, theme Cancer development and immune defence, obtained a research grant from the Dutch Cancer Society (700K Euro) to study the cell surface of cancer cells.

 

Immunotherapy using antibodies targeting the cell surface has led to important clinical advances in patients with cancer. Still, clinical responses of antibody-based therapies are limited to approximately 20-30% of cancer patients even in conjunction with chemotherapy and/or radiotherapy. One of the major scientific challenges in the oncology field is to increase our understanding why tumor cells escape from therapeutic antibodies.The aim of this project is to decipher how cell surface organization determines the efficacy of therapeutic antibodies against cancer. This will provide molecular and biological insight into the underlying mechanisms of antibody resistance, and facilitate development of a new class of therapeutic that modulates tumor cell surface organization.

There are 2 PhD candidate positions available, please contact Annemiek van Spriel if you are interested!

Related news items


T cell immunity is directed by tetraspanin CD53

5 July 2022 T cells are immune cells that are key for the defense against pathogens and cancer. T cells depend on the membrane protein CD45 to initiate T cell receptor signaling, but how CD45 is controlled at the molecular level is poorly understood. read more

A single protein complex balances the very first lineage decision of cells in human: towards foetus or placenta

21 June 2022 The international group of researchers spearheaded by Dick Zijlmans and Hendrik Marks together with colleagues from KU Leuven, examined which proteins are associated with the chromatin and how this affects gene transcription. read more

Dutch Society of Clinical Chemistry Science & Innovation Award for the team of Hans Jacobs

14 June 2022 The team of Hans Jacobs pioneers on the development of personalized diagnostics to measure minimal residual disease in patients with multiple myeloma. read more

European grants for groundbreaking Radboudumc research Professors Roshan Cools and Peter Friedl receive ERC Advanced Grant

26 April 2022

The European Research Council (ERC) is awarding grants to Roshan Cools and Peter Friedl, both professors at Radboudumc. While Cools will investigate how brains control behaviour in (stressful) situations, Friedl will work on developing a new cancer therapy.

read more

Saponin-based adjuvant-induced dendritic cell cross-presentation is dependent on PERK activation published in Cellular and Molecular Life Sciences

20 April 2022 Lisa Huis in ‘t Veld, Nataschja Ho and colleagues from the team of Gosse Adema published in Cellular and Molecular Life Sciences that Saponin-based adjuvant-induced dendritic cell cross-presentation is dependent on PERK activation. read more

Rubicon grants awarded to three RIMLS researchers

19 April 2022

Three researchers have received Rubicon funding from NWO/ZonMw. This will enable Elke Muntjewerff, Laura de Vries and Laurens van de Wiel to do research at a foreign research institute for the next two years.

read more